Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants [scRNA-Seq]

ABSTRACT: scRNAseq data set of CD11b sorted B16;B7H1 mixed mouse tumors treated with IgG or aOX40

ORGANISM(S): Mus musculus

PROVIDER: GSE225047 | GEO | 2023/03/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-03-30 | GSE224675 | GEO

T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants [bulk RNA-seq]

Project description:RNAseq data set of Ly6g+ FACS sorted mouse tumors

2023-03-30 | GSE225048 | GEO

T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants

Project description:T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants

| PRJNA933612 | ENA

T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants [scRNA-Seq]

Project description:T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants [scRNA-Seq]

| PRJNA934561 | ENA

T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants [bulk RNA-seq]

Project description:T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants [bulk RNA-seq]

| PRJNA934560 | ENA

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.

Project description:B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and single-cell whole-genome sequencing and copy number variation analysis of 30 patients treated with anti-BCMA and/or anti-GPRC5D CAR T/TCE therapy. In two cases, MM relapse post-TCE/CAR T therapy was driven by BCMA-negative clones harboring focal biallelic deletions at the TNFRSF17 locus at relapse or by selective expansion of pre-existing subclones with biallelic TNFRSF17 loss. In another five cases of relapse, newly detected, nontruncating, missense mutations or in-frame deletions in the extracellular domain of BCMA negated the efficacies of anti-BCMA TCE therapies, despite detectable surface BCMA protein expression. In the present study, we also report four cases of MM relapse with biallelic mutations of GPRC5D after anti-GPRC5D TCE therapy, including two cases with convergent evolution where multiple subclones lost GPRC5D through somatic events. Immunoselection of BCMA- or GPRC5D-negative or mutant clones is an important tumor-intrinsic driver of relapse post-targeted therapies. Mutational events on BCMA confer distinct sensitivities toward different anti-BCMA therapies, underscoring the importance of considering the tumor antigen landscape for optimal design and selection of targeted immunotherapies in MM.

| S-EPMC10504087 | biostudies-literature

Single cell RNA sequencing of thymic dendritic cells reveals molecular determinants of antigen transfer in the thymus

Project description:The presentation of self-antigens in the thymus by medullary thymic epithelial cells (mTECs) and dendritic cells (DCs) is crucial for the establishment of central tolerance. While mTECs produce and present self-antigens in an autonomous manner, DCs acquire them from mTECs by Cooperative Antigen Transfer (CAT). Although CAT represents a key process of central tolerance, molecular determinants which drive CAT are largely unknown. To reveal these determinants, we compared the transcriptomes of CAT-experienced and CAT-inexperienced DCs via scRNAseq. Specifically, we sequenced TdTOMATO+ and TdTOMATO– CD11c+ and CD11b+ cells from the thymus of Foxn1CreR26TdTOMATO mice. In this model, fluorescent TdTOMATO protein is exclusively produced by thymic epithelium, thus TdTOMATO expression in DCs (CD11c+ and CD11b+ cells) mark their previous experience of CAT. Using this approach we unraveled several candidate determinants of CAT. We focused on the gene determinant, Cldn1, encoding the tight junction protein Claudin 1, that was found to be highly expressed among the CAT-experienced type 1 lineage DCs. We performed further experiments that confirmed its role in driving CAT. In addition, this scRNAseq approach allowed us to redefine the heterogeneity and maturation states of thymic DCs.

2024-07-31 | E-MTAB-14319 | biostudies-arrayexpress

Cell specific gene silencing of lipid-siRNA conjugates in the mouse central nervous system (CNS)

Project description:We developed a lipid-siRNA conjugate, termed EG18, that potentiates prolonged gene silencing throughout the CNS after injection into CSF. To help inform viable therapeutic targets, we used scRNAseq to determine cell-specific gene silencing. Here, we used an siRNA sequencing targeting Ppib and inject 15 nmol of either Ppib-EG18 or a non-targeting control (NTC)-EG18 into the lateral ventricles of adult mice. After 1 month, brains were dissociated into single cells and bead-sorted into Cd11b+ and Cd11b- populations. The Cd11b+ dataset contains microglia and macrophages, while the Cd11b- sample comprised a sampling of other isolated perivascular and parenchymal populations. scRNAseq revealed gene silencing activity across diverse cell populations in the parenchyma and at brain borders, which may provide new avenues for disease-modifying therapies.

2024-04-30 | E-MTAB-13964 | biostudies-arrayexpress

Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple Myeloma

Project description:This SuperSeries is composed of the SubSeries listed below. B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G protein coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T. To examine the tumor intrinsic factors that promote MM antigen escape, we performed combined bulk and single cell whole genome sequencing/ copy number variation analysis of 30 patients treated with anti-BCMA and/ or -GPRC5D CAR T/ TCE. In two cases, MM relapse post TCE/ CAR T was driven by BCMA negative clones harboring focal biallelic deletions at the TNFRSF17 locus at relapse or by selective expansion of pre-existing subclones with biallelic TNFRSF17 loss. In another five cases of relapse, newly detected non-truncating missense mutations or in-frame deletions in the extracellular domain of BCMA negated the efficacies of anti-BCMA TCEs, despite detectable surface BCMA protein expression. Here, we also report the first four cases of MM relapse with biallelic mutations of GPRC5D following anti-GPRC5D TCE, including two cases with convergent evolution where multiple subclones lost GPRC5D through somatic events. Immunoselection of BCMA or GPRC5D negative or mutant clones is an important tumor intrinsic driver of relapse post targeted therapies. Mutational events on BCMA confer distinct sensitivities towards different anti-BCMA therapies, underscoring the importance of considering the tumor antigen landscape for optimal design and selection of targeted immunotherapies in MM.

2023-06-29 | GSE226336 | GEO

Single-cell transcriptional profiling reveals anti-CTLA-4 therapy remodels the intestinal immune landscape in inflammation-prone conditions

Project description:Aim: Understanding of irAE-driving mechanisms using an irAE animal model Methods: Adult Stat3Δ/Δ (STAT3 is deleted from DCs via the Cre-recombinase system) and Stat3+/+ mice were challenged with B16-OVA melanoma tumors, treated biweekly for 2 weeks with anti-CTLA-4 (clone 9H10) or control IgG. Colonic lamina propria (LP) immune cells were isolated and sorted for live CD45+ cells by fluorescence-activated cell sorting (FACS) 18-19 d after tumor establishment and following completion of therapy. Colonic LP immune cells were subjected to single-cell RNA sequencing (scRNAseq, 10x Genomics). Results: The scRNAseq data, representing 14039 cells from our 4 experimental groups, were concatenated and graphed using unsupervised clustering to identify transcriptionally-related populations. This resulted in elaboration of 19 discrete clusters, including 16 immune and 3 non-immune clusters. Conclusion:This work provides mechanistic insight into irAE development and models for pre-clinical investigation.

2022-11-01 | GSE159892 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data